4.74

8.72% 0.38

Pre-market: 4.73 -0.010 -0.21%

Nuvation Bio Inc (NUVB)

Overview News Price History Option Chain Discussions Forecast

Nuvation Bio Inc stock is traded at $4.74, with a volume of 7.58M. It is up +8.72% in the last 24 hours and down -19.11% over the past month. Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes differentiated, novel oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in their different stages of development. The company generates revenue through out-licensing collaborative agreements with its customers located in China and Japan.

Previous Close:

$4.36

Open:

$4.42

24h Volume:

7.58M

Relative Volume:

1.29

Market Cap:

$1.63B

Revenue:

$26.75M

Net Income/Loss:

$-217.48M

P/E Ratio:

-7.4039

EPS:

-0.6402

Net Cash Flow:

$-198.25M

1W Performance:

-14.75%

1M Performance:

-19.11%

6M Performance:

+38.60%

1Y Performance:

+160.44%

1-Day Range:

$4.26

$4.79

1-Week Range:

$4.16

$5.92

52-Week Range:

$1.54

$9.75

Nuvation Bio Inc Stock (NUVB) Company Profile

Name

Nuvation Bio Inc

Sector

Healthcare (1106)

Industry

Biotechnology (621)

Phone

332-208-6102

Address

1500 BROADWAY, NEW YORK

Employee

291

Twitter

Next Earnings Date

2026-03-02

Latest SEC Filings

NUVB's Discussions on Twitter

Compare NUVB vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
NUVB Nuvation Bio Inc	4.74	1.49B	26.75M	-217.48M	-198.25M	-0.6402
VRTX Vertex Pharmaceuticals Inc	477.89	120.48B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	787.50	81.05B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	749.56	46.33B	4.16B	1.29B	734.26M	19.59
ALNY Alnylam Pharmaceuticals Inc	327.30	42.26B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	299.02	32.87B	5.36B	287.73M	924.18M	2.5229

Nuvation Bio Inc Stock (NUVB) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-24-25	Initiated	Truist	Buy
Nov-19-25	Initiated	B. Riley Securities	Buy
Sep-30-25	Initiated	Jefferies	Buy
Apr-23-25	Initiated	Citizens JMP	Mkt Outperform
Mar-27-24	Upgrade	Jefferies	Hold → Buy
Mar-26-24	Upgrade	BTIG Research	Neutral → Buy
Jan-06-23	Downgrade	Jefferies	Buy → Hold
Aug-02-22	Downgrade	BMO Capital Markets	Outperform → Market Perform
Aug-02-22	Downgrade	BTIG Research	Buy → Neutral
May-04-22	Initiated	H.C. Wainwright	Buy
Oct-15-21	Resumed	BTIG Research	Buy
Apr-06-21	Initiated	RBC Capital Mkts	Outperform
Mar-08-21	Initiated	BMO Capital Markets	Outperform
Mar-08-21	Initiated	BTIG Research	Buy
Mar-08-21	Initiated	Cowen	Outperform
Mar-08-21	Initiated	Jefferies	Buy
Mar-08-21	Initiated	Wedbush	Outperform

View All

Nuvation Bio Inc Stock (NUVB) Latest News

Mar 04, 2026

Nuvation Bio (NUVB) Generates $62.9M Annual Revenue Following Successful Erozi Launch - Insider Monkey

Mar 04, 2026

NUVB: First-line patient growth, strong efficacy, and robust cash position drive positive outlook - TradingView

Mar 04, 2026

Nuvation Bio Inc. (NYSE:NUVB) Q4 2025 Earnings Call Transcript - Insider Monkey

Mar 04, 2026

Nuvation Bio Inc. Shareholders Are Encouraged to Reach Out - GlobeNewswire

Mar 04, 2026

Nuvation Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - The Malaysian Reserve

Mar 04, 2026